市場調査レポート

商品コード

1414926

免疫チェックポイント阻害薬市場：タイプ別、用途別：世界の機会分析と産業予測 2023-2032年

Immune Checkpoint Inhibitors Market By Type, By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2023年11月30日 | 発行: Allied Market Research

| ページ情報: 英文 248 Pages | 納期: 2～3営業日

価格

Cloud Access (Single User License)

USD 3,570 560,989円

レポートのクラウドアクセスでご利用頂けるライセンスです。ウェブポータルで配信され、60日間レポートにアクセスできます。この期間を過ぎるとレポートへのアクセスは失効します。コンテンツのダウンロード、印刷、共有、コピー＆ペーストはできません。

PDF (Business License)

USD 5,730 900,412円

レポートPDFをご利用いただけるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDFl内のテキスト等のコピー＆ペーストは可能です。印刷は5回可能です。追加料金を支払うことで、2～5ユーザーを収容できるようにアップグレードできます。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,508,544円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

免疫チェックポイント阻害剤（ICI）市場は、2022年には401億米ドルと評価され、2023年から2032年にかけて16.8%のCAGRで成長し、2032年には1,894億米ドルに達すると推定されています。

Immune Checkpoint Inhibitors Market-IMG1

がん細胞は、免疫システムの検出と破壊を回避するために、これらのチェックポイントを悪用します。免疫チェックポイント阻害剤は、PD-1（プログラム細胞死蛋白質1）、PD-L1（プログラム死リガンド1）、CTLA-4（細胞傷害性Tリンパ球関連蛋白質4）のような特定のタンパク質を標的とし、ブロックすることによって作用します。これらのタンパク質を阻害することにより、これらの薬剤は免疫系がより効果的にがん細胞を識別し、闘うことを可能にします。

免疫チェックポイント阻害薬市場の成長を促す主な要因は、研究開発の進展、がん患者の増加、臨床試験数の増加、研究イニシアチブの拡大、戦略的提携、新規適応症の承認拡大などです。がんは依然として世界の死亡原因のトップであり、さまざまながん種で診断される症例が増え続けています。例えば、米国国立がん研究所がん制御・人口科学部（DCCPS）によると、米国では623,405人が転移性乳がん、前立腺がん、肺がん、大腸がん、または転移性黒色腫を患っています。がんの負担が増大するにつれて、より効果的な治療選択肢に対する緊急のニーズが高まり、免疫チェックポイント阻害薬に対する需要が高まっています。

さらに、免疫チェックポイント阻害剤に焦点を当てた臨床試験の数が増加していることも、市場の成長を後押しすると予想されます。製薬会社、バイオテクノロジー企業、学術機関の間では、臨床研究にリソースを割く傾向が強まっています。この投資は、多様ながん種における免疫チェックポイント阻害剤の安全性、有効性、使用可能性を精査することを目的としています。これらの臨床試験は、新規薬剤の組み合わせの検討、治療反応の評価、予測バイオマーカーの特定に重点を置いており、免疫主導型治療の理解を広げることに大きく貢献しています。例えば、2023年7月、Merck &Co., Inc.とModerna, Inc.は、切除された高リスク（ステージIIB-IV）のメラノーマ患者における術後補助療法として、治験中の個別化新抗原療法（INT）であるV940（mRNA-4157）をMerckの抗PD-1療法であるKEYTRUDAと併用する、極めて重要な第3相ランダム化V940-001臨床試験の開始を発表しました。このような臨床試験の結果は、薬剤開拓の原動力となるだけでなく、治療方針の決定にも役立つため、免疫チェックポイント阻害薬市場の成長をさらに後押しします。

さらに、製薬企業、バイオテクノロジー企業、学術機関の戦略的提携は、免疫チェックポイント阻害薬市場の成長を促進する重要な要因として浮上しています。パートナーシップや提携は、専門知識、リソース、技術の統合を促進し、創薬・開発プロセスを迅速化します。例えば、2020年5月、世界のバイオ医薬品企業であるInnovent Biologics, Inc、とテキサス大学MDアンダーソンがんセンターは、イノベントの抗PD-1モノクローナル抗体であるTYVYT（シンチリマブ注射剤）を希少がん治療薬として米国で共同開発する戦略的提携契約を締結したと発表しました。このような共同研究により、いくつかの免疫チェックポイント阻害剤の開発・商業化に成功し、がん領域における免疫チェックポイント阻害剤の応用範囲が広がっています。

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
市場力学
- 促進要因
  - 世界のがん罹患率の増加
  - 老年人口の増加
  - 免疫チェックポイント阻害薬に対する支援的な償還政策
- 抑制要因
  - 免疫チェックポイント阻害剤の高価格
- 機会
  - パイプライン医薬品の増加
  - 新興市場における成長機会

第4章免疫チェックポイント阻害薬市場：タイプ別

概要
CTLA-4阻害剤
PD-1阻害剤
PD-L1阻害剤

第5章免疫チェックポイント阻害薬市場：用途別

概要
肺がん
膀胱がん
黒色腫
大腸がん
ホジキンリンパ腫
その他

第6章免疫チェックポイント阻害薬市場：地域別

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- その他
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- その他
ラテンアメリカ・中東・アフリカ
- ブラジル
- その他

第7章競合情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング（2022年）

第8章企業プロファイル

Merck & Co., Inc.
AstraZeneca plc
F. Hoffmann-La Roche Ltd.
Merck KGaA
Regeneron Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
BeiGene, Ltd.
Shanghai Junshi Biosciences Co., Ltd.
GlaxoSmithKline plc
Innovent Biologics, Inc.

図表

LIST OF TABLES

TABLE 01. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 02. IMMUNE CHECKPOINT INHIBITORS MARKET FOR CTLA-4 INHIBITOR, BY REGION, 2022-2032 ($MILLION)
TABLE 03. IMMUNE CHECKPOINT INHIBITORS MARKET FOR PD-1 INHIBITOR, BY REGION, 2022-2032 ($MILLION)
TABLE 04. IMMUNE CHECKPOINT INHIBITORS MARKET FOR PD-L1 INHIBITOR, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 06. IMMUNE CHECKPOINT INHIBITORS MARKET FOR LUNG CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 07. IMMUNE CHECKPOINT INHIBITORS MARKET FOR BLADDER CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 08. IMMUNE CHECKPOINT INHIBITORS MARKET FOR MELANOMA, BY REGION, 2022-2032 ($MILLION)
TABLE 09. IMMUNE CHECKPOINT INHIBITORS MARKET FOR COLORECTAL CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 10. IMMUNE CHECKPOINT INHIBITORS MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2022-2032 ($MILLION)
TABLE 11. IMMUNE CHECKPOINT INHIBITORS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 16. U.S. IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 17. U.S. IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 18. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 19. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 20. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 21. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 22. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 23. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 24. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 25. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 26. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 27. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 28. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 29. UK IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 30. UK IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 31. REST OF EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 32. REST OF EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 33. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 34. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 35. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 36. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 37. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 38. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 39. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 40. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 41. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 42. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 43. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 44. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 45. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 46. REST OF ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 47. REST OF ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 48. LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 49. LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 50. LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 51. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 52. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 53. REST OF LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 54. REST OF LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 55. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 56. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 57. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 58. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 59. MERCK & CO., INC.: KEY STRATERGIES
TABLE 60. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 61. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 62. ASTRAZENECA PLC: PRODUCT SEGMENTS
TABLE 63. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 64. ASTRAZENECA PLC: KEY STRATERGIES
TABLE 65. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 66. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 67. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 68. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 69. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 70. MERCK KGAA: KEY EXECUTIVES
TABLE 71. MERCK KGAA: COMPANY SNAPSHOT
TABLE 72. MERCK KGAA: PRODUCT SEGMENTS
TABLE 73. MERCK KGAA: PRODUCT PORTFOLIO
TABLE 74. MERCK KGAA: KEY STRATERGIES
TABLE 75. REGENERON PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 76. REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 77. REGENERON PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 78. REGENERON PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 79. REGENERON PHARMACEUTICALS, INC.: KEY STRATERGIES
TABLE 80. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 81. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 82. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
TABLE 83. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 84. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
TABLE 85. BEIGENE, LTD.: KEY EXECUTIVES
TABLE 86. BEIGENE, LTD.: COMPANY SNAPSHOT
TABLE 87. BEIGENE, LTD.: PRODUCT SEGMENTS
TABLE 88. BEIGENE, LTD.: PRODUCT PORTFOLIO
TABLE 89. BEIGENE, LTD.: KEY STRATERGIES
TABLE 90. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: KEY EXECUTIVES
TABLE 91. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: COMPANY SNAPSHOT
TABLE 92. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: PRODUCT SEGMENTS
TABLE 93. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: PRODUCT PORTFOLIO
TABLE 94. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: KEY STRATERGIES
TABLE 95. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 96. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 97. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
TABLE 98. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 99. GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 100. INNOVENT BIOLOGICS, INC.: KEY EXECUTIVES
TABLE 101. INNOVENT BIOLOGICS, INC.: COMPANY SNAPSHOT
TABLE 102. INNOVENT BIOLOGICS, INC.: PRODUCT SEGMENTS
TABLE 103. INNOVENT BIOLOGICS, INC.: PRODUCT PORTFOLIO
TABLE 104. INNOVENT BIOLOGICS, INC.: KEY STRATERGIES

LIST OF FIGURES

FIGURE 01. IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF IMMUNE CHECKPOINT INHIBITORS MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN IMMUNE CHECKPOINT INHIBITORS MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN IMMUNE CHECKPOINT INHIBITORS MARKET (2023-2032)
FIGURE 05. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
FIGURE 07. LOW THREAT OF SUBSTITUTES
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. HIGH BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR CTLA-4 INHIBITOR, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR PD-1 INHIBITOR, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR PD-L1 INHIBITOR, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR LUNG CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR BLADDER CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR MELANOMA, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR COLORECTAL CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR HODGKIN LYMPHOMA, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. IMMUNE CHECKPOINT INHIBITORS MARKET BY REGION, 2022 AND 2032(%)
FIGURE 23. U.S. IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 24. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 25. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 26. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 27. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 28. UK IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 29. REST OF EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 30. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 31. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 32. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 33. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 34. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 35. REST OF ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 36. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 37. REST OF LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 38. TOP WINNING STRATEGIES, BY YEAR (2019-2023)
FIGURE 39. TOP WINNING STRATEGIES, BY DEVELOPMENT (2019-2023)
FIGURE 40. TOP WINNING STRATEGIES, BY COMPANY (2019-2023)
FIGURE 41. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 42. COMPETITIVE DASHBOARD
FIGURE 43. COMPETITIVE HEATMAP: IMMUNE CHECKPOINT INHIBITORS MARKET
FIGURE 44. TOP PLAYER POSITIONING, 2022
FIGURE 45. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 46. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 47. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 48. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 49. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 50. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 51. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 52. MERCK KGAA: NET SALES, 2020-2022 ($MILLION)
FIGURE 53. MERCK KGAA: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 54. MERCK KGAA: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 55. REGENERON PHARMACEUTICALS, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 56. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
FIGURE 57. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 58. BEIGENE, LTD.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 59. BEIGENE, LTD.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 60. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 61. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 62. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 63. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 64. INNOVENT BIOLOGICS, INC.: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 65. INNOVENT BIOLOGICS, INC.: REVENUE SHARE BY REGION, 2021 (%)

Product Code: A03382

According to a new report published by Allied Market Research, titled, "Immune Checkpoint Inhibitors Market," The immune checkpoint inhibitors market was valued at $40.1 billion in 2022, and is estimated to reach $189.4 billion by 2032, growing at a CAGR of 16.8% from 2023 to 2032.

Cancer cells exploit these checkpoints to evade the immune system's detection and destruction. Immune checkpoint inhibitors work by targeting and blocking specific proteins, such as PD-1 (programmed cell death protein 1), PD-L1 (programmed death-ligand 1), or CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), which are involved in these checkpoints. By inhibiting these proteins, these drugs enable the immune system to more effectively identify and combat cancer cells.

The major factors driving the growth of immune checkpoint inhibitors market are advancements in R&D, increase in prevalence of cancer cases, increase in number of clinical trials, expanding research initiatives, strategic collaborations, and growing approvals for new indications. Cancer remains a leading cause of mortality globally, with continuous rise in diagnosed cases across various cancer types. For instance, National Cancer Institute, Division of Cancer Control & Population Sciences (DCCPS), stated that, 623,405 people are living with metastatic breast, prostate, lung, colorectal cancer, or metastatic melanoma in the U.S. As the burden of cancer grows, there is a pressing need for more effective treatment options, leading to the heightened demand for immune checkpoint inhibitors.

Further, increase in the number of clinical trials focusing on the immune checkpoint inhibitors is expected to fuel the market growth. There is a growing inclination among pharmaceutical companies, biotechnology firms, and academic institutions to allocate more resources toward clinical research. This investment aims to scrutinize the safety, effectiveness, and possible uses of immune checkpoint inhibitors across diverse cancer types. These trials, focused on investigating novel drug combinations, evaluating treatment reactions, and pinpointing predictive biomarkers, significantly contribute to broadening the comprehension of immune-driven treatments. For instance, in July 2023, Merck & Co., Inc., and Moderna, Inc. announced the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti-PD-1 therapy, as an adjuvant treatment in patients with resected high-risk (Stage IIB-IV) melanoma. The results from these trials not only drive drug development but also inform treatment decisions, further boosting the growth of the immune checkpoint inhibitors market.

Furthermore, strategic collaborations among pharmaceutical companies, biotechnology firms, and academic institutions have emerged as a key factor propelling the growth of the immune checkpoint inhibitors market. Partnerships and alliances facilitate the consolidation of expertise, resources, and technologies, expediting the drug discovery and development process. For instance, in May 2020, Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic & other major diseases, and The University of Texas MD Anderson Cancer Center, announced a strategic collaboration agreement to co-develop TYVYT (sintilimab injection), Innovent's anti-PD-1 monoclonal antibody, for treating rare cancers in the U.S. In addition, collaborative efforts facilitate the exploration of diverse therapeutic applications, the conduct of larger clinical trials, and the accelerated translation of research findings into clinical applications. Such collaborations have led to the successful development and commercialization of several immune checkpoint inhibitors, widening their reach and applications in oncology.

The immune checkpoint inhibitors market is segmented on the basis of product type, application, and region. By product type, the market is categorized into CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. On the basis of application, the market is classified into lung cancer, bladder cancer, melanoma, colorectal cancer, Hodgkin lymphoma, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, and rest of LAMEA).

Major key players that operate in the global immune checkpoint inhibitors market are Merck & Co., Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Merck KGaA, Regeneron Pharmaceuticals, Inc., Bristol-Myers Squibb Company, BeiGene, Ltd., Shanghai Junshi Biosciences Co., Ltd., GlaxoSmithKline plc, and Innovent Biologics, Inc. The key players have adopted strategies such as acquisition, agreement, strategic alliance, collaboration, clinical trial, expansion, joint venture, new product development, and product approval to expand their product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the immune checkpoint inhibitors market analysis from 2022 to 2032 to identify the prevailing immune checkpoint inhibitors market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the immune checkpoint inhibitors market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global immune checkpoint inhibitors market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

CTLA-4 inhibitor
PD-1 inhibitor
PD-L1 inhibitor

By Application

Lung Cancer
Bladder Cancer
Melanoma
Colorectal Cancer
Hodgkin lymphoma
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Rest of LAMEA

Key Market Players:

Merck & Co., Inc.
AstraZeneca plc
Merck KGaA
Bristol-Myers Squibb Company
BeiGene, Ltd.
Shanghai Junshi Biosciences Co., Ltd.
GlaxoSmithKline plc
Innovent Biologics, Inc.
F. Hoffmann-La Roche Ltd.
Regeneron Pharmaceuticals, Inc.

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. High bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. High bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increase in incidences of cancer across the globe
  - 3.4.1.2. Rise in geriatric population
  - 3.4.1.3. Supportive reimbursement policies for immune checkpoint inhibitors
- 3.4.2. Restraints
  - 3.4.2.1. Higher cost of immune checkpoint inhibitors
- 3.4.3. Opportunities
  - 3.4.3.1. Increase in number of pipeline drugs
  - 3.4.3.2. Growth opportunities in emerging markets

CHAPTER 4: IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. CTLA-4 inhibitor
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. PD-1 inhibitor
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. PD-L1 inhibitor
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Lung Cancer
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Bladder Cancer
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Melanoma
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Colorectal Cancer
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
5.6. Hodgkin lymphoma
- 5.6.1. Key market trends, growth factors and opportunities
- 5.6.2. Market size and forecast, by region
- 5.6.3. Market share analysis by country
5.7. Others
- 5.7.1. Key market trends, growth factors and opportunities
- 5.7.2. Market size and forecast, by region
- 5.7.3. Market share analysis by country

CHAPTER 6: IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION

6.1. Overview
- 6.1.1. Market size and forecast By Region
6.2. North America
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by Type
- 6.2.3. Market size and forecast, by Application
- 6.2.4. Market size and forecast, by country
  - 6.2.4.1. U.S.
  - 6.2.4.1.1. Market size and forecast, by Type
  - 6.2.4.1.2. Market size and forecast, by Application
  - 6.2.4.2. Canada
  - 6.2.4.2.1. Market size and forecast, by Type
  - 6.2.4.2.2. Market size and forecast, by Application
  - 6.2.4.3. Mexico
  - 6.2.4.3.1. Market size and forecast, by Type
  - 6.2.4.3.2. Market size and forecast, by Application
6.3. Europe
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by Type
- 6.3.3. Market size and forecast, by Application
- 6.3.4. Market size and forecast, by country
  - 6.3.4.1. Germany
  - 6.3.4.1.1. Market size and forecast, by Type
  - 6.3.4.1.2. Market size and forecast, by Application
  - 6.3.4.2. France
  - 6.3.4.2.1. Market size and forecast, by Type
  - 6.3.4.2.2. Market size and forecast, by Application
  - 6.3.4.3. UK
  - 6.3.4.3.1. Market size and forecast, by Type
  - 6.3.4.3.2. Market size and forecast, by Application
  - 6.3.4.4. Rest of Europe
  - 6.3.4.4.1. Market size and forecast, by Type
  - 6.3.4.4.2. Market size and forecast, by Application
6.4. Asia-Pacific
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by Type
- 6.4.3. Market size and forecast, by Application
- 6.4.4. Market size and forecast, by country
  - 6.4.4.1. Japan
  - 6.4.4.1.1. Market size and forecast, by Type
  - 6.4.4.1.2. Market size and forecast, by Application
  - 6.4.4.2. China
  - 6.4.4.2.1. Market size and forecast, by Type
  - 6.4.4.2.2. Market size and forecast, by Application
  - 6.4.4.3. India
  - 6.4.4.3.1. Market size and forecast, by Type
  - 6.4.4.3.2. Market size and forecast, by Application
  - 6.4.4.4. Australia
  - 6.4.4.4.1. Market size and forecast, by Type
  - 6.4.4.4.2. Market size and forecast, by Application
  - 6.4.4.5. South Korea
  - 6.4.4.5.1. Market size and forecast, by Type
  - 6.4.4.5.2. Market size and forecast, by Application
  - 6.4.4.6. Rest of Asia-Pacific
  - 6.4.4.6.1. Market size and forecast, by Type
  - 6.4.4.6.2. Market size and forecast, by Application
6.5. LAMEA
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by Type
- 6.5.3. Market size and forecast, by Application
- 6.5.4. Market size and forecast, by country
  - 6.5.4.1. Brazil
  - 6.5.4.1.1. Market size and forecast, by Type
  - 6.5.4.1.2. Market size and forecast, by Application
  - 6.5.4.2. Rest of LAMEA
  - 6.5.4.2.1. Market size and forecast, by Type
  - 6.5.4.2.2. Market size and forecast, by Application

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

8.1. Merck & Co., Inc.
- 8.1.1. Company overview
- 8.1.2. Key executives
- 8.1.3. Company snapshot
- 8.1.4. Operating business segments
- 8.1.5. Product portfolio
- 8.1.6. Business performance
- 8.1.7. Key strategic moves and developments
8.2. AstraZeneca plc
- 8.2.1. Company overview
- 8.2.2. Key executives
- 8.2.3. Company snapshot
- 8.2.4. Operating business segments
- 8.2.5. Product portfolio
- 8.2.6. Business performance
- 8.2.7. Key strategic moves and developments
8.3. F. Hoffmann-La Roche Ltd.
- 8.3.1. Company overview
- 8.3.2. Key executives
- 8.3.3. Company snapshot
- 8.3.4. Operating business segments
- 8.3.5. Product portfolio
- 8.3.6. Business performance
- 8.3.7. Key strategic moves and developments
8.4. Merck KGaA
- 8.4.1. Company overview
- 8.4.2. Key executives
- 8.4.3. Company snapshot
- 8.4.4. Operating business segments
- 8.4.5. Product portfolio
- 8.4.6. Business performance
- 8.4.7. Key strategic moves and developments
8.5. Regeneron Pharmaceuticals, Inc.
- 8.5.1. Company overview
- 8.5.2. Key executives
- 8.5.3. Company snapshot
- 8.5.4. Operating business segments
- 8.5.5. Product portfolio
- 8.5.6. Business performance
- 8.5.7. Key strategic moves and developments
8.6. Bristol-Myers Squibb Company
- 8.6.1. Company overview
- 8.6.2. Key executives
- 8.6.3. Company snapshot
- 8.6.4. Operating business segments
- 8.6.5. Product portfolio
- 8.6.6. Business performance
- 8.6.7. Key strategic moves and developments
8.7. BeiGene, Ltd.
- 8.7.1. Company overview
- 8.7.2. Key executives
- 8.7.3. Company snapshot
- 8.7.4. Operating business segments
- 8.7.5. Product portfolio
- 8.7.6. Business performance
- 8.7.7. Key strategic moves and developments
8.8. Shanghai Junshi Biosciences Co., Ltd.
- 8.8.1. Company overview
- 8.8.2. Key executives
- 8.8.3. Company snapshot
- 8.8.4. Operating business segments
- 8.8.5. Product portfolio
- 8.8.6. Business performance
- 8.8.7. Key strategic moves and developments
8.9. GlaxoSmithKline plc
- 8.9.1. Company overview
- 8.9.2. Key executives
- 8.9.3. Company snapshot
- 8.9.4. Operating business segments
- 8.9.5. Product portfolio
- 8.9.6. Business performance
- 8.9.7. Key strategic moves and developments
8.10. Innovent Biologics, Inc.
- 8.10.1. Company overview
- 8.10.2. Key executives
- 8.10.3. Company snapshot
- 8.10.4. Operating business segments
- 8.10.5. Product portfolio
- 8.10.6. Business performance
- 8.10.7. Key strategic moves and developments

免疫チェックポイント阻害薬市場：タイプ別、用途別：世界の機会分析と産業予測 2023-2032年

Immune Checkpoint Inhibitors Market By Type, By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章免疫チェックポイント阻害薬市場：タイプ別

第5章免疫チェックポイント阻害薬市場：用途別

第6章免疫チェックポイント阻害薬市場：地域別

第7章競合情勢

第8章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Type

By Application

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE

CHAPTER 5: IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION

CHAPTER 6: IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION

CHAPTER 7: COMPETITIVE LANDSCAPE

CHAPTER 8: COMPANY PROFILES

免疫チェックポイント阻害薬市場：タイプ別、用途別：世界の機会分析と産業予測 2023-2032年

Immune Checkpoint Inhibitors Market By Type, By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 免疫チェックポイント阻害薬市場：タイプ別

第5章 免疫チェックポイント阻害薬市場：用途別

第6章 免疫チェックポイント阻害薬市場：地域別

第7章 競合情勢

第8章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Type

By Application

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE

CHAPTER 5: IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION

CHAPTER 6: IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION

CHAPTER 7: COMPETITIVE LANDSCAPE

CHAPTER 8: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章免疫チェックポイント阻害薬市場：タイプ別

第5章免疫チェックポイント阻害薬市場：用途別

第6章免疫チェックポイント阻害薬市場：地域別

第7章競合情勢

第8章企業プロファイル